Acelyrin, Inc. (SLRN)
May 21, 2025 - SLRN was delisted (reason: merged into ALMS)
2.250
-0.020 (-0.88%)
Inactive · Last trade price
on May 21, 2025
Acelyrin Employees
Acelyrin had 83 employees as of December 31, 2024. The number of employees decreased by 52 or -38.52% compared to the previous year.
Employees
83
Change (1Y)
-52
Growth (1Y)
-38.52%
Revenue / Employee
n/a
Profits / Employee
-$3,235,145
Market Cap
227.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83 | -52 | -38.52% |
| Dec 31, 2023 | 135 | 88 | 187.23% |
| Dec 31, 2022 | 47 | - | - |
SLRN News
- 9 days ago - ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - GlobeNewsWire
- 16 days ago - Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis - GlobeNewsWire
- 21 days ago - ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - GlobeNewsWire
- 5 weeks ago - ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN - Business Wire
- 2 months ago - ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - GlobeNewsWire
- 2 months ago - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger - GlobeNewsWire
- 2 months ago - ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - GlobeNewsWire
- 3 months ago - ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences - GlobeNewsWire